Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study.

Vincenzo MessinaLorenzo OnoratoGiovanni Di CaprioErnesto ClaarVincenzo IovinellaAntonio RussoValerio RosatoAngela SalzilloRiccardo NevolaFilomena SimeoneFabio CurcioMariantonietta PisaturoNicola Coppola

Published in: Life (Basel, Switzerland) (2020)

Treatment with DAAs led to a high SVR12 rate (97.9%) in a large cohort of HCV-infected PWID. The only predictor of viral failure found in our analysis was treatment with first- and second-generation DAA.

Keyphrases

hepatitis c virus
combination therapy
human immunodeficiency virus
smoking cessation
replacement therapy